Dirk suggesting that at this time, as long as active IBD excluded, relatively reassuring low rates of new onset IBD with IL17a inhibition #ACR19 @rheumnow 4M064 https://t.co/R1eAEObR5P

If 50% of SpA pts have microscopic bowel disease, 10% have clinically significant bowel disease...should all patients diagnosed with SpA undergo a colonoscopy with biopsies? #ACR19 @RheumNow

Exciting phase 2 data on bimekizumab (dual anti-17A and F) in r-axSpA, looks like 160mg is the go, I hear on the grapevine that they are well into phase 3. Looking forward to the results #ACR19 @RheumNow Abs 3S111 https://t.co/PTCgjWm2EM

Previous smoking hx increase risk of UC, but this goes into remission almost immediately when they resume smoking...“The good thing about that is that they stay on their maintenance therapy.” -Dr David Rubin #ACR19 @RheumNow

5 of 6 patients with CRIA (Cleavage-Resistant RIPK1-Induced Autoinflammatory) responded well to tocilizumab. @AmandaOmbrello #ACR19 @rheumnow

occurrence of extra-articulations manifestations is high & increases over time #ACR19 @rheumnow 4M064 https://t.co/QC62S7cvPk

If appendix removed by age 25 for true appendicitis, won’t get UC (can still get crohns)...fascinating 🤔 -Dr D Rubin #ACR19 @RheumNow

Holy Molly! TNFi (etanercept, adalimumab, infliximab, or golimumab) completely prevented stokes in patients with DADA2. #ACR19 @RheumNow

#ACR19 @rheumnow ABS1513 Tofacitinib efficacy in PSA ⬇️ if BL BMI ≥ 35 . Safety consistent across all BL BMI categories. 3 CV events: non-fatal cerebrovascular accident, TIA(both Tofa 5 mg BID, BMI ≥ 30 – < 35), and artery revascularization in PBO; BMI ≥ 35 https://t.co/Y8htX6qETV

#ACR19 @rheumnow abs1913 Cohort study confirms the association of HLA-B*15 with peripheral joint involvement in AS but not in PSA, suggesting different mechanisms may be in play in the pathogenesis of peripheral joint and entheseal involvement between AS &PSA https://t.co/NdaHqI63oH

@AmandaOmbrello from ⁦@NIH_NIAMS⁩ at #ACR19 : #Rheumatologists... Have you come across Adult-Onset Sporadic #PolyarteritisNodosa ?... 🚨 Don’t forget to check for ADA2 mutation!!! 🚨 @ACRheum @RheumNow https://t.co/1MP0wsD6Vr

60% The percentage of patients at @NIH's autoinflammatory disease cohort that are undifferentiated and do not have a specific disease diagnosis -Dr. Amanda Ombrello. #ACR19 @rheumnow https://t.co/d85OtnEA8o

H2H Vedo vs Ada for gut disease (not joint)(no dose escalation in this trial) #ACR19 @rheumnow 4M064 https://t.co/30JhLETdAK

Panel on podcasting in rheumatology led by @RheumNow with @AdamJBrownMD @hausmannMD @EBRheum and myself. #ACR19 https://t.co/W1EMXe2qsd

Shared & separate targets for autoimmune bowel disease & SpA. Nice summary #ACR19 @rheumnow 4M064 https://t.co/5Mz7pM0hPv